Raleigh Capital Management Inc. Has $1.62 Million Stake in Johnson & Johnson (NYSE:JNJ)

Raleigh Capital Management Inc. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 63.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,963 shares of the company’s stock after buying an additional 3,859 shares during the period. Raleigh Capital Management Inc.’s holdings in Johnson & Johnson were worth $1,615,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Plimoth Trust Co. LLC grew its stake in Johnson & Johnson by 0.6% during the third quarter. Plimoth Trust Co. LLC now owns 35,234 shares of the company’s stock worth $5,710,000 after purchasing an additional 217 shares during the period. Northwest Investment Counselors LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $180,000. Livelsberger Financial Advisory acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $112,000. Retirement Guys Formula LLC lifted its position in shares of Johnson & Johnson by 7.5% during the 3rd quarter. Retirement Guys Formula LLC now owns 5,622 shares of the company’s stock valued at $911,000 after acquiring an additional 394 shares during the period. Finally, Border to Coast Pensions Partnership Ltd grew its holdings in Johnson & Johnson by 4.5% in the third quarter. Border to Coast Pensions Partnership Ltd now owns 260,931 shares of the company’s stock worth $42,163,000 after purchasing an additional 11,131 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on JNJ shares. Wells Fargo & Company increased their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. TD Cowen dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Royal Bank of Canada boosted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Finally, Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $175.93.

Johnson & Johnson Stock Down 1.4 %

Shares of NYSE:JNJ opened at $162.85 on Tuesday. The firm has a fifty day moving average price of $163.04 and a two-hundred day moving average price of $154.77. The company has a market cap of $391.92 billion, a price-to-earnings ratio of 10.15, a PEG ratio of 2.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the previous year, the business earned $2.66 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.05%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.